Cengild Medical Berhad (0243) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Cengild Medical Berhad stock MYR 0.13, price MYR 0.15, that is 13.3% below the price, quality 43 out of 100. Rating: overvalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
55‑month range 0.1500 MYR – 0.5179 MYR · fair‑value band 0.1200 MYR – 0.1600 MYR · the 0.1500 MYR price screens above the 0.1300 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow Cengild Medical Berhad in your weekly email
Every Wednesday you see whether Cengild Medical Berhad is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Cengild Medical Berhad, an investment holding company, operates a medical center in Malaysia.
Show moreShow less
The company offers various care and treatment consultant services for gastrointestinal and liver diseases, morbid obesity, and oncology and urological conditions; general cardiology and gynecology assessment; gastroenterology and hepatology; anesthesiology, general surgery, internal medicine, and radiology; ear, nose and throat; gastrointestinal surgeries, including upper gastrointestinal, hepatobiliary, pancreatic, colorectal surgery, and bariatric surgery; and chemotherapy.
It also provides medical management services; nursing services and clinical support services; clinical laboratory and pharmacy; operating theatre, endoscopy, radiology and imaging services; accident and emergency care, and health screenings; and consultant services.
Cengild Medical Berhad was founded in 2017 and is based in Kuala Lumpur, Malaysia.
Stock analysis
Cengild Medical Berhad (0243) currently trades at 0.1500 MYR, while our model-based Fair Value estimate is 0.1300 MYR, 13% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 0.2400 MYR per share, and 7 of the 15 models we run sit above the 0.1500 MYR price.
Bear case: the Earnings-Based group reads lowest at 0.0500 MYR, and 8 of the 15 models stay below the price. Data coverage for this calculation is low.
Scenario range: 0.1200 MYR (bear) to 0.1600 MYR (bull), the price of 0.1500 MYR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Cengild Medical Berhad reported revenue of 73.2M MYR in FY2026 versus 64.4M MYR in FY2022, a compound +3.2%/yr. Reported net income was 11.4M MYR in FY2026, compounding +5.1%/yr from FY2022.
Key figures
Market cap 129M MYR (≈ $31.7M) Micro · P/E ratio 15.0 · P/S ratio 2.34 · EPS (TTM) 0.0100 MYR · Dividend yield 2.7% · Net margin 15.6% · Return on equity 9.8% · Return on assets (EBIT) 9.3% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 57 out of 100 (low confidence).
What moves the price
The share trades about 37% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −13%, 0243 screens richer than that median.
Fair Value models
Bear0.1200 MYRFair Value 0.1300 MYRBull0.1600 MYR
Price 0.1500 MYR · Downside -13.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 4 months old). Earnings retained since then (0.0022 MYR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.25/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−8.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.9%
Start year 2021 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.0%
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in MYR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in MYR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+6.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.7%
Dividend (yield on the price)2.7%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.23% → 19%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 234 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score43 · Bottom 25%
Fair Value upside−13.3% · Below median
Profitability
Return on equity (12 months)9.8% · Above median
Return on assets5.1% · Above median
Net margin (12 months)15.6% · Top 25%
Operating margin (12 months)19.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)0.3% · Bottom 25%
Dividend yield (12 months)2.7% · Above median
Balance sheet
Debt / equity0.70× · Highest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Cengild Medical Berhad Fair Value". https://www.fairvalue-calculator.com/stock/0243
Frequently asked questions
Is Cengild Medical Berhad (0243) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 0.1300 MYR versus a price of 0.1500 MYR, about 13% lower (overvalued).
What is the fair value of 0243?
Our model-based fair value for Cengild Medical Berhad is 0.1300 MYR (as of Nov 3, 2026), built from audited fundamentals. The current price: 0.1500 MYR.
What is the quality score of 0243?
Cengild Medical Berhad has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cengild Medical Berhad (0243)?
Our model-based price target is the fair value of 0.1300 MYR (as of Nov 3, 2026) from 15 valuation models. Cautious scenario 0.1200 MYR, optimistic scenario 0.1600 MYR. It is a calculation from audited fundamentals, not an analyst target.
What is the Cengild Medical Berhad stock forecast for 2026?
Our models put fair value at 0.1300 MYR, about 13% lower versus a price of 0.1500 MYR (overvalued). Cautious scenario 0.1200 MYR, optimistic scenario 0.1600 MYR. The calculation is refreshed regularly with new filings.
What is the revenue of Cengild Medical Berhad (0243)?
Cengild Medical Berhad reported trailing-twelve-month revenue of about 73.2M MYR (latest available figure, as of Nov 3, 2026).
Does Cengild Medical Berhad pay a dividend?
Cengild Medical Berhad currently shows a dividend yield of 2.67% relative to its recent price (as of Nov 3, 2026).
How much is the dividend of Cengild Medical Berhad (0243) and when is the ex-dividend date?
Cengild Medical Berhad pays a dividend of 0.004 MYR per share a year, a dividend yield of 2.7%. The last ex-dividend date was Sep 11, 2026. A dividend has been paid every year since at least 2022. The payout ratio is 40.0% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Cengild Medical Berhad (0243)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cengild Medical Berhad it is 0.1300 MYR per share (as of Nov 3, 2026), against a price of 0.1500 MYR. It is the blended result of 15 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Cengild Medical Berhad stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 0243 trades above its calculated fair value: price 0.1500 MYR, fair value 0.1300 MYR, a gap of about −13% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0243?
No. The price is what the market pays today (0.1500 MYR); the fair value is what the company's own numbers justify (0.1300 MYR). For Cengild Medical Berhad the two are 0.0200 MYR per share apart. That gap is exactly why we show both numbers side by side.
How much is Cengild Medical Berhad worth?
The market values Cengild Medical Berhad at about 129M MYR (market capitalisation, as of Nov 3, 2026). Per share that is 0.1500 MYR; our models calculate a fair value of 0.1300 MYR per share.
What do the bullish and bearish scenarios say about 0243?
Our models span a range for Cengild Medical Berhad: cautious scenario 0.1200 MYR, base 0.1300 MYR, optimistic 0.1600 MYR per share (as of Nov 3, 2026, price 0.1500 MYR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0243?
Cengild Medical Berhad trades at a price-to-earnings ratio of 15.0 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 0.1300 MYR is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2022 to 2026), reported earnings: 23.7. Other multiples: P/B 1.1, P/S 1.8, EV/EBITDA 11.2.
How solid is the balance sheet of Cengild Medical Berhad (0243)?
Balance-sheet figures for Cengild Medical Berhad (as of Nov 3, 2026): return on equity 9.8%, debt of 0.70 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 0243 from its 52-week high?
Cengild Medical Berhad trades at 0.1500 MYR, about 37% below its 52-week high of 0.2366 MYR and at the low of 0.1500 MYR (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 0.1300 MYR is for.
Which stocks are comparable to Cengild Medical Berhad?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cengild Medical Berhad stock attractive at the current price?
The data as of Nov 3, 2026: price 0.1500 MYR, calculated fair value 0.1300 MYR (−13%), Quality Score 43/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0243 calculated?
We run Cengild Medical Berhad through 15 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 0.1300 MYR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Cengild Medical Berhad itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cengild Medical Berhad (0243)?
The closing price on Nov 6, 2026 was 0.1500 MYR. Our model-based fair value is 0.1300 MYR, about 13% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cengild Medical Berhad right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Cengild Medical Berhad
How large is the market capitalisation of Cengild Medical Berhad (0243)?
The market capitalisation of Cengild Medical Berhad is 129M MYR (≈ $31.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cengild Medical Berhad (0243)?
The price-to-sales ratio of Cengild Medical Berhad is 2.34 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cengild Medical Berhad (0243)?
Earnings per share at Cengild Medical Berhad are 0.0100 MYR (price ÷ EPS = P/E 15.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Cengild Medical Berhad (0243)?
The dividend yield of Cengild Medical Berhad is 2.7% (payout 40.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Cengild Medical Berhad (0243)?
The net margin of Cengild Medical Berhad is 15.6% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cengild Medical Berhad (0243)?
The return on equity (ROE) of Cengild Medical Berhad is 9.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cengild Medical Berhad (0243)?
On an EBIT basis the return on assets of Cengild Medical Berhad is 9.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cengild Medical Berhad (0243)?
The operating margin of Cengild Medical Berhad is 19.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cengild Medical Berhad (0243)?
Revenue at Cengild Medical Berhad is growing +0.3% versus a year earlier (3y avg +1.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Cengild Medical Berhad (0243)?
Earnings per share at Cengild Medical Berhad are growing +91.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Cengild Medical Berhad (0243) generate?
The free cash flow of Cengild Medical Berhad is −68.2M MYR (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cengild Medical Berhad (0243) carry?
The net debt of Cengild Medical Berhad is 76.1M MYR (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Cengild Medical Berhad in the live analysis
One click puts Cengild Medical Berhad on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 3, 2026